MBX Biosciences (MBX) vs Maravai LifeSciences (MRVI)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
MBX Biosciences (MBX) has outperformed Maravai LifeSciences (MRVI) over the past year, gaining 245.2% versus a gain of 116.5%. Maravai LifeSciences is the larger company by market cap ($2.67 billion vs $2.56 billion), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | MBX | MRVI |
|---|---|---|
| Share price | $53.25 | $7.21 |
| Market cap | $2.56B | $2.67B |
| 1-day change | -2.37% | -2.96% |
| YTD return | +72.92% | +121.85% |
| 1-year return | +245.19% | +116.52% |
| 5-year return | — | -80.56% |
| EPS (TTM) | $-2.37 | $-0.53 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | — | $185.74M |
| Revenue growth (YoY) | — | -28.34% |
| Net income (latest FY) | $-87.00M | $-130.77M |
| Gross margin | — | 18.30% |
| Operating margin | — | -115.89% |
| Net margin | — | -70.41% |
| 52-week high | $72.64 | $9.42 |
| 52-week low | $12.94 | $2.55 |
| Distance from 52-week high | -26.69% | -23.46% |
| Analyst consensus | strong_buy | buy |
| Avg. price target upside | +77.09% | +8.60% |
| Average volume | 539.34K | 3.33M |
| Shares outstanding | 48.16M | 148.99M |
| Employees | 63 | 415 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- MBX has outperformed MRVI by 128.7 percentage points over the past year.
About MBX Biosciences
MBX stock →MBX Biosciences, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of precision peptide therapies for the treatment of endocrine and metabolic disorders. Its lead product candidate is Canvuparatide (MBX 2109), a parathyroid hormone peptide prodrug, which is in Phase 3 clinical trial for the treatment of chronic hypoparathyroidism.
Health Care · Biotechnology: Pharmaceutical Preparations · 63 employees
About Maravai LifeSciences
MRVI stock →Maravai LifeSciences Holdings, Inc., a life sciences company, provides products that enable the development of drug therapies, vaccines, drug therapies, cell and gene therapies, and diagnostics North America, Europe, the Middle East, Africa, the Asia Pacific, and Latin and Central America. It operates through two segments: TRILINK and CYGNUS.
Health Care · Biotechnology: Pharmaceutical Preparations · 415 employees
MBX vs MRVI FAQ
Which is bigger, MBX Biosciences or Maravai LifeSciences?
Maravai LifeSciences (MRVI) is larger, with a market capitalization of $2.67B compared with $2.56B for MBX Biosciences (MBX).
Which stock has performed better over the past year, MBX or MRVI?
MBX returned +245.19% over the past 12 months, compared with +116.52% for MRVI (price return, excluding dividends). Past performance does not predict future results.
Are MBX Biosciences and Maravai LifeSciences in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.